EBNA3C Augments Pim-1 Mediated Phosphorylation and Degradation of p21 to Promote B-Cell Proliferation

PLoS Pathogens

Volumn 10, Issue 8, 2014, Pages

  Banerjee, Shuvomoy ^a   Lu, Jie ^a   Cai, Qiliang ^b   Sun, Zhiguo ^a   Jha, Hem Chandra ^a   Robertson, Erle S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 3C; ETOPOSIDE; PROTEIN KINASE PIM 1; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; EBNA-3C, EPSTEIN-BARR VIRUS;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; BIOSYNTHESIS; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; HEK293 CELL LINE; IMMUNOPRECIPITATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; VIRUS CELL TRANSFORMATION; WESTERN BLOTTING;

B-LYMPHOCYTES; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-PIM-1; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84928044072     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004304     Document Type: Article

References (102)

1. Henle G, Henle W, Clifford P, Diehl V, Kafuko GW, et al. (1969) Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst 43: 1147–1157.
2. Jang HS, Cho JO, Yoon CY, Kim HJ, Park JC, (2001) Demonstration of Epstein-Barr virus in odontogenic and nonodontogenic tumors by the polymerase chain reaction (PCR). J Oral Pathol Med 30: 603–610.
3. Raab-Traub N, (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12: 431–441.
4. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E, (2007) Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7: 166–175.
5. Nourse JP, Jones K, Gandhi MK, Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 11: 888–895.
6. Hsu JL, Glaser SL, (2000) Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 34: 27–53.
7. Cesarman E, Mesri EA, (1999) Virus-associated lymphomas. Curr Opin Oncol 11: 322–332.
8. Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, et al. (1993) Epstein-Barr virus in gastric carcinoma. Am J Pathol 143: 1250–1254.
9. Henle W, Diehl V, Kohn G, Zur Hausen H, Henle G, (1967) Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157: 1064–1065.
10. Young LS, Dawson CW, Eliopoulos AG, (2000) The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol 53: 238–247.
11. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, et al. (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.
12. Zhao B, Mar JC, Maruo S, Lee S, Gewurz BE, et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 108: 337–342.
13. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, et al. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919–1924.
14. Subramanian C, Knight JS, Robertson ES, (2002) The Epstein Barr nuclear antigen EBNA3C regulates transcription, cell transformation and cell migration. Front Biosci 7: d704–716.
15. Robertson ES, Lin J, Kieff E, (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70: 3068–3074.
16. Allday MJ, Farrell PJ, (1994) Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68: 3491–3498.
17. Knight JS, Lan K, Subramanian C, Robertson ES, (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77: 4261–4272.
18. Subramanian C, Robertson ES, (2002) The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. J Virol 76: 8702–8709.
19. Cai Q, Guo Y, Xiao B, Banerjee S, Saha A, et al. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog 7: e1002418.
20. Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, et al. (2008) Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82: 4082–4090.
21. Yi F, Saha A, Murakami M, Kumar P, Knight JS, et al. (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236–247.
22. Saha A, Halder S, Upadhyay SK, Lu J, Kumar P, et al. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog 7: e1001275.
23. Brault L, Gasser C, Bracher F, Huber K, Knapp S, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95: 1004–1015.
24. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, et al. (2009) PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362–375.
25. Hu YL, Passegue E, Fong S, Largman C, Lawrence HJ, (2007) Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 109: 4732–4738.
26. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, et al. (1989) The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A 86: 8857–8861.
27. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, et al. (2007) Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467–1475.
28. Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ, (2000) Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 19: 1215–1224.
29. Gapter LA, Magnuson NS, Ng KY, Hosick HL, (2006) Pim-1 kinase expression during murine mammary development. Biochem Biophys Res Commun 345: 989–997.
30. Moroy T, Grzeschiczek A, Petzold S, Hartmann KU, (1993) Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice. Proc Natl Acad Sci U S A 90: 10734–10738.
31. Saris CJ, Domen J, Berns A, (1991) The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 10: 655–664.
32. Palaty CK, Kalmar G, Tai G, Oh S, Amankawa L, et al. (1997) Identification of the autophosphorylation sites of the Xenopus laevis Pim-1 proto-oncogene-encoded protein kinase. J Biol Chem 272: 10514–10521.
33. Palaty CK, Clark-Lewis I, Leung D, Pelech SL, (1997) Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 75: 153–162.
34. Bullock AN, Debreczeni J, Amos AL, Knapp S, Turk BE, (2005) Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 280: 41675–41682.
35. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, et al. (2002) Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45–55.
36. Zhang Y, Wang Z, Magnuson NS, (2007) Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5: 909–922.
37. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, et al. (1999) Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659–18666.
38. Wang Z, Bhattacharya N, Meyer MK, Seimiya H, Tsuruo T, et al. (2001) Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys 390: 9–18.
39. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, et al. (2002) Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111: 80–95.
40. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Moroy T, (2004) The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279: 48319–48328.
41. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, et al. (2006) The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 38: 430–443.
42. Pircher TJ, Zhao S, Geiger JN, Joneja B, Wojchowski DM, (2000) Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene 19: 3684–3692.
43. Bajaj BG, Verma SC, Lan K, Cotter MA, Woodman ZL, et al. (2006) KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology 351: 18–28.
44. Kim JH, Kim WS, Yun Y, Park C, Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cell Signal 22: 1858–1863.
45. Rainio EM, Ahlfors H, Carter KL, Ruuska M, Matikainen S, et al. (2005) Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity. Virology 333: 201–206.
46. Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, et al. E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog 8: e1002573.
47. Maunders MJ, Petti L, Rowe M, (1994) Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. J Gen Virol 75 (Pt 4): 769–778.
48. Peltola K, Hollmen M, Maula SM, Rainio E, Ristamaki R, et al. (2009) Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 11: 629–636.
49. Walpen T, Kalus I, Schwaller J, Peier MA, Battegay EJ, et al. Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation. Biochem Biophys Res Commun 429: 24–30.
50. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83: 4652–4669.
51. Banerjee S, Lu J, Cai Q, Saha A, Jha HC, et al. The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog 9: e1003314.
52. Knight JS, Sharma N, Robertson ES, (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A 102: 18562–18566.
53. Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, et al. (2008) Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 49: 2081–2090.
54. Mahadevan D, Spier C, Della Croce K, Miller S, George B, et al. (2005) Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 4: 1867–1879.
55. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, et al. (2004) Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571: 43–49.
56. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, et al. (2002) Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 99: 2175–2180.
57. Rainio EM, Sandholm J, Koskinen PJ, (2002) Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 168: 1524–1527.
58. Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM, (2000) Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett 467: 17–21.
59. Maita H, Harada Y, Nagakubo D, Kitaura H, Ikeda M, et al. (2000) PAP-1, a novel target protein of phosphorylation by pim-1 kinase. Eur J Biochem 267: 5168–5178.
60. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, et al. (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2: 167–179.
61. Abbas T, Dutta A, (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414.
62. Vlachostergios PJ, Voutsadakis IA, Papandreou CN, The ubiquitin-proteasome system in glioma cell cycle control. Cell Div 7: 18.
63. Amador V, Ge S, Santamaria PG, Guardavaccaro D, Pagano M, (2007) APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 27: 462–473.
64. Dotto GP, (2000) p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471: M43–56.
65. Coqueret O, (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65–70.
66. Sherr CJ, Roberts JM, (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501–1512.
67. Besson A, Dowdy SF, Roberts JM, (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159–169.
68. Cottage CT, Bailey B, Fischer KM, Avitable D, Collins B, et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ Res 106: 891–901.
69. Wang J, Anderson PD, Luo W, Gius D, Roh M, et al. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 31: 1794–1803.
70. Fulda S, Debatin KM, (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798–4811.
71. Fulda S, Debatin KM, (2004) Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 4: 569–576.
72. Gartel AL, Radhakrishnan SK, (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980–3985.
73. Zhi X, Zhao D, Wang Z, Zhou Z, Wang C, et al. E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res 73: 385–394.
74. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, et al. (1984) Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37: 141–150.
75. Swords R, Kelly K, Carew J, Nawrocki S, Mahalingam D, et al. The Pim kinases: new targets for drug development. Curr Drug Targets 12: 2059–2066.
76. Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, et al. (2003) Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 23: 167–178.
77. Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, et al. (2005) Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105: 3671–3678.
78. Ayala GE, Dai H, Ittmann M, Li R, Powell M, et al. (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64: 6082–6090.
79. Bachmann M, Moroy T, (2005) The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726–730.
80. White RE, Groves IJ, Turro E, Yee J, Kremmer E, et al. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5: e13979.
81. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ, Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.
82. Kaul R, Murakami M, Choudhuri T, Robertson ES, (2007) Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J Virol 81: 10352–10361.
83. Knight JS, Sharma N, Kalman DE, Robertson ES, (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78: 12857–12867.
84. Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, et al. (2001) Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 281: 663–669.
85. Shay KP, Wang Z, Xing PX, McKenzie IF, Magnuson NS, (2005) Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 3: 170–181.
86. Saha A, Robertson ES, Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis. Future Microbiol 8: 323–352.
87. Knight JS, Sharma N, Robertson ES, (2005) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25: 1749–1763.
88. Touitou R, O'Nions J, Heaney J, Allday MJ, (2005) Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 86: 1269–1277.
89. Jha HCAJM, Saha A, Banerjee S, Lu J, et al. Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol 88: 3776–3788.
90. Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, et al. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem 285: 29128–29137.
91. Selten G, Cuypers HT, Zijlstra M, Melief C, Berns A, (1984) Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J 3: 3215–3222.
92. Amaravadi R, Thompson CB, (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618–2624.
93. Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC, (1999) Two posttranscriptional pathways that regulate p21(Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res 247: 168–175.
94. Jarviluoma A, Child ES, Sarek G, Sirimongkolkasem P, Peters G, et al. (2006) Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 26: 2430–2440.
95. O'Nions J, Allday MJ, (2003) Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 22: 7181–7191.
96. Zhu N, Ramirez LM, Lee RL, Magnuson NS, Bishop GA, et al. (2002) CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol 168: 744–754.
97. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, et al. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28: 2581–2592.
98. Hernandez AM, Colvin ES, Chen YC, Geiss SL, Eller LE, et al. (2013) Upregulation of p21 activates the intrinsic apoptotic pathway in beta cells. Am J Physiol Endocrinol Metab 304: E1281–90.
99. Lu J, Verma SC, Murakami M, Cai Q, Kumar P, et al. (2009) Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation. J Virol 83: 7129–7141.
100. Halder S, Murakami M, Verma SC, Kumar P, Yi F, et al. (2009) Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4: e7214.
101. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
102. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, et al. (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759–1767.